We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Construction of Molecular Subtypes and Related Prognostic and Immune Response Models Based on M2 Macrophages in Glioblastoma.
- Authors
Xiao, Kai; Zhao, Shushan; Yuan, Jian; Pan, Yimin; Song, Ya; Tang, Lanhua
- Abstract
Keywords: glioblastoma; M2 macrophage; prognosis; immunotherapy; molecular subtypes EN glioblastoma M2 macrophage prognosis immunotherapy molecular subtypes 913 926 14 02/16/22 20220101 NES 220101 Kai Xiao, SP 1 sp Shushan Zhao, SP 2 sp Jian Yuan, SP 1 sp Yimin Pan, SP 1 sp Ya Song, SP 2 sp Lanhua Tang SP 3, sp SP 4 sp SP 1 sp Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, People's Republic of China; SP 2 sp Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, People's Republic of China; SP 3 sp Department of Oncology, Xiangya Hospital, Central South University, Changsha, People's Republic of China; SP 4 sp National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, People's Republic of China Correspondence: Lanhua Tang Department of Oncology, Xiangya Hospital, Central South University, Changsha, People's Republic of China Email [email protected] Introduction Glioblastoma multiforme (GBM) is the most aggressive and deadliest primary brain tumor of adults.[1] Although many treatments, including surgical resection with chemotherapy and radiotherapy, may improve the outcome, the median survival time is still only 14-16 months[2] and the 5-year survival rate is just 9.8%.[3] GBM is a biologically heterogeneous intracranial neoplasm and it has most of the classical hallmarks of a tumor. The fractions of M2 macrophages and M2 macrophage-related immune genes were identified, and then clustering of the GBM by M2 macrophages was conducted and the M2score was established successfully. Discussion Based on morphological similarities, GBM has traditionally been classified into gliosarcoma, giant cell GBM and epithelioid GBM by the WHO Classification of Tumors of the Central Nervous System (CNS).[32] With features containing both neoplastic cells and stroma, GBM has histological heterogeneity, with disappointing prognosis.
- Subjects
BRAIN tumors; IMMUNE response; MACROPHAGES; CENTRAL nervous system tumors; GLIOBLASTOMA multiforme
- Publication
International Journal of General Medicine, 2022, Vol 15, p913
- ISSN
1178-7074
- Publication type
Article
- DOI
10.2147/IJGM.S343152